aTyr Pharma (LIFE) Competitors

Harvard Bioscience (NASDAQ:HBIO) and aTyr Pharma (NASDAQ:LIFE) are both small-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability.

Do analysts rate HBIO or LIFE?

aTyr Pharma has a consensus target price of $23.67, indicating a potential upside of 1,268.02%. Given Harvard Bioscience's higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
aTyr Pharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the MarketBeat Community prefer HBIO or LIFE?

aTyr Pharma received 54 more outperform votes than Harvard Bioscience when rated by MarketBeat users. However, 72.02% of users gave Harvard Bioscience an outperform vote while only 61.52% of users gave aTyr Pharma an outperform vote.

Company	Underperform	Outperform
Harvard Bioscience	Outperform Votes 368 72.02%	Underperform Votes 143 27.98%
aTyr Pharma	Outperform Votes 422 61.52%	Underperform Votes 264 38.48%

Do insiders & institutionals believe in HBIO or LIFE?

80.9% of Harvard Bioscience shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 9.0% of Harvard Bioscience shares are held by company insiders. Comparatively, 3.7% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Is HBIO or LIFE more profitable?

aTyr Pharma has a net margin of 0.00% compared to aTyr Pharma's net margin of -8.18%. aTyr Pharma's return on equity of 0.26% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-8.18%	0.26%	0.14%
aTyr Pharma	N/A	-56.92%	-43.87%

Which has more risk and volatility, HBIO or LIFE?

Harvard Bioscience has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.

Does the media favor HBIO or LIFE?

In the previous week, Harvard Bioscience had 11 more articles in the media than aTyr Pharma. MarketBeat recorded 14 mentions for Harvard Bioscience and 3 mentions for aTyr Pharma. Harvard Bioscience's average media sentiment score of 1.31 beat aTyr Pharma's score of 0.15 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harvard Bioscience	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
aTyr Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation and earnings, HBIO or LIFE?

Harvard Bioscience has higher revenue and earnings than aTyr Pharma. Harvard Bioscience is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$106.79M	1.29	-$3.41M	-$0.20	-15.85
aTyr Pharma	$588K	203.04	-$50.39M	-$0.90	-1.92

Summary

Harvard Bioscience beats aTyr Pharma on 10 of the 17 factors compared between the two stocks.